{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:04:36Z","timestamp":1774620276477,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"crossref","award":["NET-2018-12367032-2"],"award-info":[{"award-number":["NET-2018-12367032-2"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15762-4","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:47:11Z","timestamp":1771649231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["End\u2011of\u2011life care in advanced melanoma: a retrospective cohort study from an Italian comprehensive cancer center"],"prefix":"10.1186","volume":"26","author":[{"given":"Michela","family":"De Mattia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-5578","authenticated-orcid":false,"given":"Andrea","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Delucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Blondeaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agostina","family":"Lagodin D\u2019Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Giannubilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Pronzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Bighin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica Teresa","family":"Tanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"issue":"1","key":"15762_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2025;392(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"2","key":"15762_CR2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","volume":"21","author":"MR Migden","year":"2020","unstructured":"Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21(2):294\u2013305.","journal-title":"Lancet Oncol"},{"issue":"12","key":"15762_CR3","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","volume":"35","author":"GV Long","year":"2024","unstructured":"Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol. 2024;35(12):1191\u20139.","journal-title":"Ann Oncol"},{"issue":"2","key":"15762_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.annonc.2023.10.123","volume":"35","author":"KD Lewis","year":"2024","unstructured":"Lewis KD, Peris K, Sekulic A, Stratigos AJ, Dunn L, Eroglu Z, et al. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Ann Oncol. 2024;35(2):221\u20138.","journal-title":"Ann Oncol"},{"key":"15762_CR5","doi-asserted-by":"crossref","unstructured":"D\u2019Angelo SP, Lebb\u00e9 C, Mortier L, Brohl AS, Fazio N, Grob JJ et al. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study. ESMO Open . 2024;9(5). Available from: https:\/\/www.esmoopen.com\/article\/S2059-7029(24)01229-8\/fulltext Cited 11 Sept 2025.","DOI":"10.1016\/j.esmoop.2024.103461"},{"issue":"8","key":"15762_CR6","doi-asserted-by":"publisher","first-page":"e012478","DOI":"10.1136\/jitc-2025-012478","volume":"13","author":"G Grignani","year":"2025","unstructured":"Grignani G, Rutkowski P, Lebb\u00e9 C, Guida M, Gaudy-Marqueste C, Spagnolo F, et al. Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201). J Immunother Cancer. 2025;13(8):e012478.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"15762_CR7","doi-asserted-by":"publisher","first-page":"e2426641","DOI":"10.1001\/jamanetworkopen.2024.26641","volume":"7","author":"OJ van Not","year":"2024","unstructured":"van Not OJ, van den Eertwegh AJM, Jalving H, Bloem M, Haanen JB, van Rijn RS, et al. Long-Term Survival in Patients With Advanced Melanoma. JAMA Netw Open. 2024;7(8):e2426641.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"15762_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","volume":"18","author":"MR Middleton","year":"2000","unstructured":"Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18(1):158\u201366.","journal-title":"J Clin Oncol"},{"issue":"12","key":"15762_CR9","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ejca.2004.04.030","volume":"40","author":"AMM Eggermont","year":"2004","unstructured":"Eggermont AMM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004;40(12):1825\u201336.","journal-title":"Eur J Cancer"},{"issue":"3","key":"15762_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11912-022-01203-5","volume":"24","author":"A An","year":"2022","unstructured":"An A, Hui D. Immunotherapy Versus Hospice: Treatment Decision-Making in the Modern Era of Novel Cancer Therapies. Curr Oncol Rep. 2022;24(3):285\u201394.","journal-title":"Curr Oncol Rep"},{"issue":"20","key":"15762_CR11","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. N Engl J Med. 2014;371(20):1877\u201388.","journal-title":"N Engl J Med"},{"key":"15762_CR12","unstructured":"Melanoma Research. Available from: https:\/\/journals.lww.com\/melanomaresearch\/fulltext\/2022\/12000\/long_term_survival_of_patients_with_advanced.8.aspx. Cited 11 Sept 2025."},{"key":"15762_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12885-021-08165-0","volume":"21","author":"F Spagnolo","year":"2021","unstructured":"Spagnolo F, Boutros A, Cecchi F, Croce E, Tanda ET, Queirolo P. Treatment beyond progression with anti-PD-1\/PD-L1 based regimens in advanced solid tumors: a systematic review. BMC Cancer. 2021;21:425.","journal-title":"BMC Cancer"},{"issue":"6","key":"15762_CR14","doi-asserted-by":"publisher","first-page":"5266","DOI":"10.3390\/curroncol30060400","volume":"30","author":"M Mannucci","year":"2023","unstructured":"Mannucci M, Fontana V, Campanella D, Filiberti RA, Pronzato P, Rosa A. A Descriptive Study of Repeated Hospitalizations and Survival of Patients with Metastatic Melanoma in the Northern Italian Region during 2004\u20132019. Curr Oncol. 2023;30(6):5266\u201378.","journal-title":"Curr Oncol"},{"issue":"9","key":"15762_CR15","first-page":"1297","volume":"19","author":"A Forschner","year":"2021","unstructured":"Forschner A, Loquai C, Meiss F, Huening S, Pawlowski J, Bradfisch F, et al. Is there an overtreatment of melanoma patients at the end of their life? Results of a multicenter study on 193 melanoma patients. J Dtsch Dermatol Ges. 2021;19(9):1297\u2013305.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"7","key":"15762_CR16","first-page":"2201","volume":"26","author":"I Massa","year":"2018","unstructured":"Massa I, Balzi W, Altini M, Bert\u00e8 R, Bosco M, Cassinelli D, et al. The challenge of sustainability in healthcare systems: frequency and cost of diagnostic procedures in end-of-life cancer patients. Support Care Cancer. 2018;26(7):2201\u20138.","journal-title":"Support Care Cancer"},{"issue":"1","key":"15762_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/s12913-017-2472-0","volume":"17","author":"J Fernandes","year":"2017","unstructured":"Fernandes J, Bregman B, Combemale P, Amaz C, de L\u00e9otoing L, Vainchtock A, et al. Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment). BMC Health Serv Res. 2017;17(1):542.","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"15762_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/bjd.14631","volume":"175","author":"I Gallais S\u00e9r\u00e9zal","year":"2016","unstructured":"Gallais S\u00e9r\u00e9zal I, Beaussant Y, Rochigneux P, Tournigand C, Aubry R, Lindel\u00f6f B, et al. End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study. Br J Dermatol. 2016;175(3):583\u201392.","journal-title":"Br J Dermatol"},{"key":"15762_CR19","unstructured":"Berloto S, Meda F, Longo F. Le cure palliative in Italia : una fotografia del settore. Mecosan : management ed economia sanitaria : 116, 4, 2020. 2020;89\u2013111."},{"issue":"5","key":"15762_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jpainsymman.2024.01.029","volume":"67","author":"M Hua","year":"2024","unstructured":"Hua M, Guo L, Ing C, Lackraj D, Wang S, Morrison RS. Specialist Palliative Care Use and End-of-Life Care in Patients With Metastatic Cancer. J Pain Symptom Manage. 2024;67(5):357\u2013e36515.","journal-title":"J Pain Symptom Manage"},{"issue":"21","key":"15762_CR21","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.3390\/cancers13215271","volume":"13","author":"RSJM Schmitz","year":"2021","unstructured":"Schmitz RSJM, Geurts SME, Ibragimova KIE, Tilli DJP, Tjan-Heijnen VCG, de Boer M. Healthcare Use during the Last Six Months of Life in Patients with Advanced Breast Cancer. Cancers. 2021;13(21):5271.","journal-title":"Cancers"},{"issue":"1","key":"15762_CR22","doi-asserted-by":"publisher","first-page":"107327482097717","DOI":"10.1177\/1073274820977175","volume":"27","author":"A Tanguy-Melac","year":"2020","unstructured":"Tanguy-Melac A, Denis P, Fagot-Campagna A, Gastaldi-M\u00e9nager C, Laurent M, Tuppin P. Intensity of Care, Expenditure, and Place of Death in French Women in the Year Before Their Death From Breast Cancer: A Population-Based Study. Cancer Control. 2020;27(1):1073274820977175.","journal-title":"Cancer Control"},{"key":"15762_CR23","unstructured":"The value of. embedding: integrated palliative care for patients with metastatic breast cancer | Breast Cancer Research and Treatment . Available from: https:\/\/link.springer.com\/article\/10.1007\/s10549-017-4556-2.\u00a0Cited 17 Nov 2025."},{"issue":"6","key":"15762_CR24","first-page":"CD011129","volume":"6","author":"MW Haun","year":"2017","unstructured":"Haun MW, Estel S, R\u00fccker G, Friederich HC, Villalobos M, Thomas M, et al. Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev. 2017;6(6):CD011129.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"15762_CR25","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1001\/jamainternmed.2014.5271","volume":"174","author":"RE Bernacki","year":"2014","unstructured":"Bernacki RE, Block SD, American College of Physicians High Value Care Task Force. Communication about serious illness care goals: a review and synthesis of best practices. JAMA Intern Med. 2014;174(12):1994\u20132003.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"15762_CR26","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1177\/0269216315586659","volume":"29","author":"J Dixon","year":"2015","unstructured":"Dixon J, Matosevic T, Knapp M. The economic evidence for advance care planning: Systematic review of evidence. Palliat Med. 2015;29(10):869\u201384.","journal-title":"Palliat Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15762-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15762-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15762-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:59:01Z","timestamp":1774616341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15762-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15762"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15762-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EB reports speaker fee from Eli Lilly and Astrazeneca, funding (to the Institution) from Gilead ScienceML reports advisory role for Roche, Lilly, Novartis, AstraZeneca, Pfizer, Seagen, Gilead, MSD, Pierre Fabre, Menarini, Nordic Pharma, Bayer and Exact Sciences; receiving speaker honoraria from Roche, Lilly, Novartis, Pfizer, Sandoz, Libbs, Daiichi Sankyo, Takeda, Ipsen, Menarini and AstraZeneca; receiving travel grants from Gilead, Roche, and Daiichi Sankyo; receiving research funding (to his institution) from Gilead. The other authors declare no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"412"}}